Apr 22, 2025 / 12:00PM GMT
Sarah Howell - Arecor Therapeutics PLC - Chief Executive Officer
Particularly after a long bank holiday weekend, so as my name's Doctor Sarah Howell, and I'm the CEO of Arecor Therapeutics, and delighted to be joined today by David Ellam.
So many of you will know that David joined us as interim CFO back in November of last year and very pleased to be able to confirm that he's now joined us permanently and of course, David will be talking us through the financials later in the presentation today. So we'll be talking through the results for Arecor Therapeutics for the year ending December 31, 2024.
So our customary legal notice, of course. So just to give a very high level, I know certainly everybody in the room today knows the company very well by now, but Arecor are very much focused on transforming patient care by bringing enhanced therapeutics to market that reduce patient burden whilst improving outcomes. We do this by leveraging our innovative and proprietary formulation.
Technology platform Arestat to develop novel formulations of existing therapeutics with these enhanced
Full Year 2024 Arecor Therapeutics PLC Earnings Call Transcript
Apr 22, 2025
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers